1-12 of 12
Ahmed Idbaih
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D. Kaulen, Jakob Ito, Martin van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaih, Julien Dômont, Paul M. Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3892–3900.
https://doi.org/10.1158/1078-0432.CCR-23-0926
Published: 02 October 2023
View article titled, Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Open the PDF for Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Kaspar Draaisma, C. Mircea S. Tesileanu, Iris de Heer, Martin Klein, Marion Smits, Jaap C. Reijneveld, Paul M. Clement, Filip Y.F. de Vos, Antje Wick, Paul J. Mulholland, Martin J.B. Taphoorn, Michael Weller, Olivier L. Chinot, Johan M. Kros, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih, Pierre A. Robe, Martin J. van den Bent, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2440–2448.
https://doi.org/10.1158/1078-0432.CCR-21-3725
Published: 01 June 2022
View article titled, Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Open the PDF for Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial in another window
Includes: Supplementary data
Journal Articles

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides, Pierre-Hugues Roche, Stéphane Fuentes, Emeline Tabouret, Maryline Barrie, Anita Cohen, Stéphane Honoré, Mohamed Boucekine, Karine Baumstarck, Dominique Figarella-Branger, Anne Barlier, Henry Dufour, Olivier Louis Chinot
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 552–557.
https://doi.org/10.1158/1078-0432.CCR-19-2109
Published: 03 February 2020
View article titled, Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Open the PDF for Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial in another window
Includes: Supplementary data
Journal Articles

Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

Ahmed Idbaih, Michael Canney, Lisa Belin, Carole Desseaux, Alexandre Vignot, Guillaume Bouchoux, Nicolas Asquier, Bruno Law-Ye, Delphine Leclercq, Anne Bissery, Yann De Rycke, Clementine Trosch, Laurent Capelle, Marc Sanson, Khe Hoang-Xuan, Caroline Dehais, Caroline Houillier, Florence Laigle-Donadey, Bertrand Mathon, Arthur André, Cyril Lafon, Jean-Yves Chapelon, Jean-Yves Delattre, Alexandre Carpentier
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3793–3801.
https://doi.org/10.1158/1078-0432.CCR-18-3643
Published: 01 July 2019
View article titled, Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
Open the PDF for Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

Maite Verreault, Charlotte Schmitt, Lauriane Goldwirt, Kristine Pelton, Samer Haidar, Camille Levasseur, Jeremy Guehennec, David Knoff, Marianne Labussière, Yannick Marie, Azra H. Ligon, Karima Mokhtari, Khê Hoang-Xuan, Marc Sanson, Brian M. Alexander, Patrick Y. Wen, Jean-Yves Delattre, Keith L. Ligon, Ahmed Idbaih
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1185–1196.
https://doi.org/10.1158/1078-0432.CCR-15-1015
Published: 29 February 2016
View article titled, Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <em>MDM2</em>-Amplified and <em>TP53</em> Wild-type Glioblastomas
Open the PDF for Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <em>MDM2</em>-Amplified and <em>TP53</em> Wild-type Glioblastomas in another window
Includes: Supplementary data
Journal Articles

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Anna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, Marianne Labussiere, Karima Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boisselier, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Idbaih, Caroline Houillier, Feng R. Luo, Jean-Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petrecca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, Antonio Iavarone
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3307–3317.
https://doi.org/10.1158/1078-0432.CCR-14-2199
Published: 14 July 2015
View article titled, Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Open the PDF for Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma in another window
Includes: Supplementary data
Journal Articles

MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Martin J. van den Bent, Lale Erdem-Eraslan, Ahmed Idbaih, Johan de Rooi, Paul H.C. Eilers, Wim G.M. Spliet, Wilfred F.A. den Dunnen, Cees Tijssen, Pieter Wesseling, Peter A.E. Sillevis Smitt, Johan M. Kros, Thierry Gorlia, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5513–5522.
https://doi.org/10.1158/1078-0432.CCR-13-1157
Published: 01 October 2013
View article titled, <em>MGMT</em>-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
Open the PDF for <em>MGMT</em>-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 in another window
Includes: Supplementary data
Journal Articles

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

Alberto Gonzalez-Aguilar, Ahmed Idbaih, Blandine Boisselier, Naïma Habbita, Marta Rossetto, Alice Laurenge, Aurélie Bruno, Anne Jouvet, Marc Polivka, Clovis Adam, Dominique Figarella-Branger, Catherine Miquel, Anne Vital, Hervé Ghesquières, Rémy Gressin, Vincent Delwail, Luc Taillandier, Olivier Chinot, Pierre Soubeyran, Emmanuel Gyan, Sylvain Choquet, Caroline Houillier, Carole Soussain, Marie-Laure Tanguy, Yannick Marie, Karima Mokhtari, Khê Hoang-Xuan
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5203–5211.
https://doi.org/10.1158/1078-0432.CCR-12-0845
Published: 30 September 2012
View article titled, Recurrent Mutations of <em>MYD88</em> and <em>TBL1XR1</em> in Primary Central Nervous System Lymphomas
Open the PDF for Recurrent Mutations of <em>MYD88</em> and <em>TBL1XR1</em> in Primary Central Nervous System Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy

Benjamin Ribba, Gentian Kaloshi, Mathieu Peyre, Damien Ricard, Vincent Calvez, Michel Tod, Branka Čajavec-Bernard, Ahmed Idbaih, Dimitri Psimaras, Linda Dainese, Johan Pallud, Stéphanie Cartalat-Carel, Jean-Yves Delattre, Jérôme Honnorat, Emmanuel Grenier, François Ducray
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5071–5080.
https://doi.org/10.1158/1078-0432.CCR-12-0084
Published: 16 September 2012
View article titled, A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
Open the PDF for A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy in another window
Includes: Supplementary data
Journal Articles

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Lariesa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevis Smitt, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7148–7155.
https://doi.org/10.1158/1078-0432.CCR-11-1274
Published: 14 November 2011
View article titled, A Hypermethylated Phenotype Is a Better Predictor of Survival than <em>MGMT</em> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Open the PDF for A Hypermethylated Phenotype Is a Better Predictor of Survival than <em>MGMT</em> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951 in another window
Includes: Supplementary data
Journal Articles

Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma

Matthias Simon, Fay J. Hosking, Yannick Marie, Konstantinos Gousias, Blandine Boisselier, Catherine Carpentier, Johannes Schramm, Karima Mokhtari, Khe Hoang-Xuan, Ahmed Idbaih, Jean-Yves Delattre, Mark Lathrop, Lindsay B. Robertson, Richard S. Houlston, Marc Sanson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5252–5259.
https://doi.org/10.1158/1078-0432.CCR-10-1502
Published: 31 October 2010
View article titled, Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma
Open the PDF for Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma in another window
Journal Articles

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Cees C. Tijssen, Denis Lacombe, Ahmed Idbaih, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, Marc Sanson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1597–1604.
https://doi.org/10.1158/1078-0432.CCR-09-2902
Published: 28 February 2010
View article titled, <em>IDH1</em> and <em>IDH2</em> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Open the PDF for <em>IDH1</em> and <em>IDH2</em> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group in another window